18503327. LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES simplified abstract (SANOFI)
Contents
- 1 LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES
Organization Name
Inventor(s)
Timothy Tibbitts of Paris (FR)
Angela Lynne Beaulieu of Paris (FR)
Rebecca L. Goldman of Paris (FR)
Hardip Rajeshbhai Gopani of Paris (FR)
Asad Khanmohammed of Paris (FR)
Natalia Vargas Montoya of Paris (FR)
Ashish L. Sarode of Paris (FR)
LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES - A simplified explanation of the abstract
This abstract first appeared for US patent application 18503327 titled 'LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES
Simplified Explanation
The abstract describes a patent application for novel lipid nanoparticles designed to deliver nucleic acids such as mRNA. The patent also includes methods for producing and utilizing these lipid nanoparticles for nucleic acid delivery.
- Lipid nanoparticles developed for delivering nucleic acids like mRNA
- Methods provided for making and using lipid nanoparticles for nucleic acid delivery
Potential Applications
The technology can be applied in the fields of gene therapy, vaccine development, and drug delivery systems.
Problems Solved
This innovation addresses the challenge of efficiently delivering nucleic acids, such as mRNA, into cells for therapeutic purposes.
Benefits
The lipid nanoparticles offer a more effective and targeted delivery system for nucleic acids, potentially improving the efficacy of gene therapy and vaccine development.
Potential Commercial Applications
"Revolutionizing Nucleic Acid Delivery: Applications in Gene Therapy and Vaccine Development"
Possible Prior Art
Prior art may include existing lipid nanoparticle delivery systems for nucleic acids or other drug delivery technologies.
Unanswered Questions
How does this technology compare to existing lipid nanoparticle delivery systems for nucleic acids?
The article does not provide a direct comparison with other lipid nanoparticle systems.
What are the specific methods used to manufacture these lipid nanoparticles for nucleic acid delivery?
The article does not detail the specific manufacturing processes involved in creating these lipid nanoparticles.
Original Abstract Submitted
Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.
- SANOFI
- Danilo Casimiro of Paris (FR)
- Sudha Chivukula of Paris (FR)
- Kirill Kalnin of Paris (FR)
- Timothy Plitnik of Paris (FR)
- Timothy Tibbitts of Paris (FR)
- Angela Lynne Beaulieu of Paris (FR)
- Frank Derosa of Paris (FR)
- Anusha Dias of Paris (FR)
- Rebecca L. Goldman of Paris (FR)
- Hardip Rajeshbhai Gopani of Paris (FR)
- Shrirang Karve of Paris (FR)
- Asad Khanmohammed of Paris (FR)
- Natalia Vargas Montoya of Paris (FR)
- Priyal Patel of Paris (FR)
- Ashish L. Sarode of Paris (FR)
- Khang Anh Tran of Paris (FR)
- A61K9/127
- A61K39/145
- A61K39/39
- A61P31/16